The human antimicrobial peptide LL-37 is known to have chemotactic and modulatory activities on various cells including monocytes, T cells, and epithelial cells. Given that LL-37 enhances chemotactic attraction and modulates the activity of DCs, it is conceivablethat it might play a role as an immune adjuvant by skewing the immune environment toward immunostimulatory conditions. In this study, we characterized the mucosal adjuvant activity of LL-37 using model and pathogenic Ags. When LL-37-conjugated Ag was administered orally to mice, a tolerogenic Peyer's patch environment was altered to cell populations containing IL-6-secreting CD11c + , CD11c + CD70 + , and Th17 cells capable of evoking a subsequent LL-37-conjugated Ag-specific immune response in both systemic and mucosal immune compartments. In addition, we showed presentation of formyl peptide receptor, an LL-37 receptor, on M cells, which may aid the initiation of an LL-37-mediated enhanced immune response through targeting and transcytosis of the conjugated Ag. Based on our findings, we conclude that LL-37 has potential as an oral mucosal adjuvant, not only by enhancing the delivery of LL-37-conjugated Ag to M cells, but also by triggering T-cell-mediated Ag-specific immune responses through modulation of the mucosal immune environment.Keywords: Antimicrobial peptide r LL-37 r Mucosal immunity r Systemic immunity r Th17Additional supporting information may be found in the online version of this article at the publisher's web-site
IntroductionThe mucosal surface is continuously exposed to microbiota, food antigens (Ags), and allergens [1]. To protect the body from foreign Correspondence: Dr. Yong-Suk Jang e-mail: yongsuk@jbnu.ac.kr Ags, the gastrointestinal mucosa coordinates a specialized immune system in which Peyer's patches (PPs) and mesenteric lymph nodes (MLNs) serve as mucosal immune inductive sites and the lamina propria (LP) serves as a mucosal effector site [2]. In the mucosal immune system, secretory immunoglobulin A (SIgA) plays a major defensive role by inhibiting pathogen adhesion and neutralizing viruses and toxins [3]. Production of SIgA can be achieved through both T-cell-independent and T-cell-dependent pathways in PPs.C 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu Eur. J. Immunol. 2015. 45: 1402-1413 Immunomodulation 1403 Production of SIgA by a T-cell-independent pathway is rapidly developed in response to Toll-like receptor (TLR) signaling or by inducing the expression of B-cell-activating factor belonging to the TNF family (BAFF) in innate immune cells, although this SIgA has low affinity [4]. In contrast, induction of IgA + -cell development by a T-cell-dependent pathway takes place in the germinal center (GC) and is orchestrated by follicular dendritic cells (FDCs). This process takes approximately 5 to 7 days and requires stimulation by cytokine signals, including TGF-β, . This T-cell-dependent GC pathway induces the development of highaffinity Ag-specific SIgA and isotype-switched memory cells, which in tu...